Display Settings:

Format

Send to:

Choose Destination
    J Immunol. 2008 Jul 1;181(1):155-64.

    Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses.

    Source

    Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA.

    Abstract

    Cancer immunosurveillance failure is largely attributed to insufficient activation signals and dominant inhibitory stimuli for tumor Ag (TAg)-specific CD8 T cells. CD4 T cells have been shown to license dendritic cells (DC), thereby having the potential for converting CD8 T cell responses from tolerance to activation. To understand the potential cooperation of TAg-specific CD4 and CD8 T cells, we have characterized the responses of naive TCR transgenic CD8 and CD4 T cells to poorly immunogenic murine tumors. We found that whereas CD8 T cells sensed TAg and were tolerized, the CD4 T cells remained ignorant throughout tumor growth and did not provide help. This disparity in responses was due to normal TAg MHC class I cross-presentation by immature CD8alpha+ DC in the draining lymph node, but poor MHC class II presentation on all DC subsets due to selective inhibition by the tumor microenvironment. Thus, these results reveal a novel mechanism of cancer immunosubversion, in which inhibition of MHC-II TAg presentation on DC prevents CD4 T cell priming, thereby blocking any potential for licensing CD8alpha+ DC and helping tolerized CD8 T cells.

    PMID:
    18566380
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2587216
    Free PMC Article

    Images from this publication.See all images (9) Free text

    Figure 1
    Figure 3
    Figure 9
    Figure 8
    Figure 7
    Figure 4
    Figure 5
    Figure 6
    Figure 2

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk